Drug Stock Hits Record Low After FDA Rejection

Options traders were call-heavy towards HRB ahead of earnings

Managing Editor
Jun 13, 2018 at 3:32 PM
facebook X logo linkedin

U.S. stocks are trading mixed, after the Fed raised its key interest rate, and increased its 2018 rate-hike forecast. While the Nasdaq continues to outperform, individual stocks making big moves today include tax preparation concern H & R Block Inc (NYSE:HRB), home energy solutions specialist Enphase Energy Inc (NASDAQ:ENPH), and drug stock scPharmaceuticals Inc (NASDAQ:SCPH). Below, we will take a closer look at how shares of HRB, ENPH, and SCPH are trading on the charts.

HRB Nosedives on Weak Forecast

HRB has plunged 16.7% to trade at $24.65 -- fresh off a new annual low of $23.33 --  after the company issued a weak full-year revenue and margin forecast, which overshadowed the tax preparer's fiscal fourth-quarter earnings and revenue beats. What's more, the security saw its price target cut at BMO (to $25) and Morgan Stanley (to $27).

Heading into today, the stock was trading in year-to-date-high territory, and speculative players were betting on even bigger gains. Data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) shows HRB with a 10-day call/put volume ratio of 2.63 -- in the 79th annual percentile. This ratio suggests H & R Block calls have been purchased over puts at a faster-than-usual clip during the past two weeks.

Echoing this, HRB stock's Schaeffer's put/call open interest ratio (SOIR) of 0.52 ranks in the 13th percentile of its annual range. In other words, traders are more call-heavy than usual among options set to expire in three months or less.

M&A Buzz Sends ENPH to Top of Nasdaq

Enphase stock is one of Nasdaq's top performers today, up 32.6% at $5.97, after the company revealed plans to buy SunPower (SPWR)'s microinverter sector for $25 million in cash and 7.5 million ENPH shares. Today's surge echoes the stock's longer-term trend, with ENPH up 627% year-over-year, and not far from its May 31 two-year peak at $6.37. Plus, the equity's recent pullback from here was quickly contained by its 80-day moving average.

In response, ENPH received price-target hikes from Cowen and Company (to $6.75) and H.C. Wainwright (to $9). This bullish sentiment is not unusual for the stock, where currently six out of seven firms following the energy stock sport a "strong buy" recommendation.

Short sellers have started to cover their record-high position, too. In the most recent reporting period, short interest on ENPH fell 1% from its May 1 all-time peak of 9.89 million shares, but still represents over 15% of the stock's total available float. At Enphase stock's average daily trading volume, it would take almost a week for shorts to cover their remaining bearish bets.

scPharmaceuticals' Edema Therapy Failed to Get FDA Approval

scPharmaceuticals stock is one of the worst stocks on the Nasdaq, after the U.S. Food and Drug Administration (FDA) rejected the company's edema drug, Furoscix. This plunge comes less than two weeks after the FDA released a letter of deficiencies in the drug, sending SCPH to its worst day ever. At last check, scPharmaceuticals is down 23% at $5.86, earlier hitting a record low of $5.61, and down 52% year-to-date.

The drug concern has been trading publicly for less than a year, and three brokerage firms follow it. The sentiment among these analyst is upbeat, with all three sporting "strong buy" ratings, while SCPH's average 12-month price target of $23.33 comes in at a more than 240% premium to current levels.

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI